The Bloodgen Project of the European Union, 2003–2009

• Published in: Transfusion medicine and hemotherapy Vol. 36; no. 3; pp. 162 - 167
• Main Authors: Avent, Neil D., Martinez, Antonio, Flegel, Willy A., Olsson, Martin L., Scott, Marion L., Nogués, Núria, Píšacka, Martin, Daniels, Geoff L., Muñiz-Diaz, Eduardo, Madgett, Tracey E., Storry, Jill R., Beiboer, Sigrid, Maaskant-van Wijk, Petra M., von Zabern, Inge, Jiménez, Elisa, Tejedor, Diego, López, Mónica, Camacho, Emma, Cheroutre, Goedele, Hacker, Anita, Jinoch, Pavel, Svobodova, Irena, van der Schoot, Ellen, de Haas, Masja
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger GmbH 01-01-2009
• Subjects: Blood group antigens; Blood groups; BLOODchip; Clinical Medicine; Hematologi; Hematology; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Review Article · Übersichtsarbeit; Review · Übersichtsarbeit; Blood group antigens; Blood groups; BLOODchip
• ISSN: 1660-3796; 1660-3818; 1660-3818
• DOI: 10.1159/000218192

The Bloodgen project was funded by the European Commission between 2003 and 2006, and involved academic blood centres, universities, and Progenika Biopharma S.A., a commercial supplier of genotyping platforms that incorporate glass arrays. The project has led to the development of a commercially available product, BLOODchip, that can be used to comprehensively genotype an individual for all clinically significant blood groups. The intention of making this system available is that blood services and perhaps even hospital blood banks would be able to obtain extended information concerning the blood group of routine blood donors and vulnerable patient groups. This may be of significant use in the current management of multi-transfused patients who become alloimmunised due to incomplete matching of blood groups. In the future it can be envisaged that better matching of donor-patient blood could be achieved by comprehensive genotyping of every blood donor, especially regular ones. This situation could even be extended to genotyping every individual at birth, which may prove to have significant long-term health economic benefits as it may be coupled with detection of inborn errors of metabolism.